TikTok can harm your teen's mental health: Dr. Marc Siegel
Fox News medical contributor Dr. Marc Siegel discusses the dangers of receiving medical advice from social media platforms on 'Varney & Co.'
Deadly fungus and companies with potential treatment
The U.S. Food and Drug Administration approved Cidara Therapeutics and Melinta Therapeutics' antifungal drug for patients with little to no other options.
Moderna COVID vaccines expected to cost $130
Moderna plans to charge $130 for a single dose of its COVID vaccine, according to a recent report. That's in line with what Pfizer said it would for its version.
Moderna adding 2,000 new workers this year
Moderna will add to its workforce and its U.S. real estate footprint, the biotech company announced in a press release Friday. The employees will be added by the end of the year.
US probe of dog breeder scrutinizes why USDA left thousands of beagles to suffer
USDA took no action against drug maker Envigo who had to forfeit 4,000 beagles after mistreating them. Envigo settled civil charges but Grand Jury explores legal options.
New drugs are coming to market at sky-high prices
To avoid government penalties for raising drug prices, pharmaceutical companies are releasing drugs at higher prices with hefty rebates to maintain profitability.
Biden's budget is a 'fiscal atrocity': Steve Moore
Former Trump senior economic adviser Steve Moore blasted Biden's proposed 'tax and spend' budget, arguing it would kill the economy, stifle growth and crush investors on 'Cavuto: Coast to Coast.'
Dr. Fauci was going to thwart ‘any effort’ to investigate the Wuhan lab: Sen. Marsha Blackburn
Sen. Marsha Blackburn, R-Tenn., discusses the ongoing investigation into the origins of COVID-19 and Biden’s mismanaged military withdrawal from Afghanistan on ‘Mornings with Maria.’
Dr. Janette Nesheiwat issues warning on Ozempic: Medicine is not just meant to help you ‘look better'
Fox News medical contributor Dr. Janette Nesheiwat joined ‘Mornings with Maria’ to discuss Ozempic, a drug used to treat diabetes that has grown in popularity for its weight loss side effects.
Biden's fiscal path is not sustainable: Phillip Swagel
Congressional Budget Office Director Phillip Swagel discusses Biden's plan to address social security insolvency in his federal budget proposal on 'Cavuto: Coast to Coast.'
Congress investigates how pharma middlemen affect drug prices
House Republicans are investigating pharmacy-benefit managers, middlemen in drug price negotiations, over whether they create unnecessary costs for prescription drugs.
Macroeconomy, inflation a 'driver' of risk preference at the CEO, board level: Mark Shafir
Citi Co-Head of Global Mergers and Acquisitions Mark Shafir discusses his outlook for the M&A and IPO market.
US needs to look at China as a 'serious threat': Rep. Anna Paulina Luna
Rep. Anna Paulina Luna, R-Fla., discusses the Biden administration's handling of the Chinese surveillance mission over the U.S., negotiations over the debt ceiling and Biden's claims that the GOP will cut Social Security and Medicare.
Artificial intelligence will be proliferated across all of Stryker: CEO Kevin Lobo
Stryker CEO Kevin Lobo discusses whether the expected surge in the orthopedics markets will drive sales in 2023 on 'The Claman Countdown.'
Ozempic, Wegovy help with weight loss but the rebound is real: Dr. Nicole Saphier
Fox News medical contributor Dr. Nicole Saphier discusses the dangers of using the diabetes drug Ozempic for weight loss on 'The Big Money Show.'
US Appeals Court sides with drugmakers on discount program
Drugmakers win battle in Third Circuit Court of Appeals over Health Resources and Services Administration, as courts decided HRSA went beyond the law with regulatory overreach.
Drug-shipping giant AmerisourceBergen gets 'fresh, bold' new name in Cencora
AmerisourceBergen chairman and CEO Steven Collis explains why the drug wholesale company is changing its name to Cencora on 'The Claman Countdown.'
The IRS is coming after middle America: Sen. Bill Hagerty
Sen. Bill Hagerty, R-Tenn., discusses the new GOP bill that would ban the IRS' $600 reporting requirement and reacts to claims that the GOP is targeting cuts to Social Security, Medicare, and Medicaid.
Johnson & Johnson fourth-quarter earnings down 25%
The company continues to see pressure on sales from staffing shortages at hospitals, which have limited growth in procedures using J&J products, while inflation has boosted expenses.
FDA rejects Lilly’s alzheimer’s drug candidate, seeks more data
Lilly said it would work with the FDA to evaluate the fastest pathway to get its Alzheimer’s drug to market after what it believes was a successful trial.